---

Aflibercept (Eylea): Treatment of Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

---

A 96-week PULSAR subgroup analysis: Similar visual and anatomic improvements with aflibercept 8 mg every 12 weeks or longer and 2 mg every 8 weeks, as defined by baseline BCVA, CRT, CNV type, and race

---

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

---

Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability

---

Case 2: Treatment-Experienced nAMD Switch to Aflibercept 8mg

---

Early Real-World Experiences With Faricimab and Aflibercept 8mg

---

ASRS 2024: Real-world efficacy and safety of aflibercept 8 mg in neovascular AMD